摘要
肺动脉高压(PAH)为一种少见的慢性疾病,其危害性大、致死率高,多发于老年人和妇女。随着我国步入老龄化社会,对PAH的防治越发重视。综述了包括CCBs、PDE-5抑制剂、ERAs和PGI2类常规靶点和鸟苷酸环化酶激动剂,5-羟色胺,Bcr-Abl蛋白络氨酸激酶抑制剂,Rho-激酶抑制剂,内皮祖细胞和基因等治疗该疾病的新型作用靶点在内的最新靶点与药物的研究进展,以及新一代药物的发展方向。
Pulmonary arterial hypertension （PAH） is a rare chronic disease with severe harm and a high mortality,and happens mainlyin the elderly and women.Currently,as China is entering the aging society,more and more researches put the emphasis on thetreatments of PAH.In this paper,it reviews the advanced development about new targets and drugs for treating this disease,such ascalcium channel blockers （CCBs）,phosphodiesterase-5 （PDE-5） inhibitors,endothelin receptor antagonist （ERAs）,and prostacyclin（PGI2）,and new target consisting of guanylyl cyclase agonist,serotonin,Bcr-Abl protein tyrosine kinase inhibitors,Rho-kinaseinhibitors,endothelial progenitors,and genes.In addition,it also introduces the direction of the new generation of drugs in the future.
出处
《现代药物与临床》
CAS
2012年第6期543-554,共12页
Drugs & Clinic
关键词
肺动脉高压
内皮素受体拮抗剂
磷酸二酯酶-5
新药创制
新靶点
pulmonary arterial hypertension （PAH）
endothelin receptor antagonist （ERAs）
phosphodiesterase-5 （PDE-5）
innovationin pharmaceutics
new targets
